| Code | Description | Claims | Beneficiaries | Total Paid |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
48,880 |
44,272 |
$3.70M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
31,458 |
28,366 |
$2.79M |
| 94760 |
|
27,124 |
24,593 |
$2.35M |
| 36415 |
Collection of venous blood by venipuncture |
14,148 |
13,226 |
$2.18M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
20,806 |
19,467 |
$1.92M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,784 |
1,432 |
$1.55M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
22,183 |
20,093 |
$1.06M |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
6,297 |
6,123 |
$1.04M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
931 |
589 |
$1.02M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
13,097 |
12,946 |
$842K |
| 99188 |
|
11,784 |
11,578 |
$812K |
| 83655 |
|
7,322 |
7,158 |
$811K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
17,321 |
17,047 |
$675K |
| 99215 |
Prolong outpt/office vis |
4,086 |
3,388 |
$592K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
5,819 |
5,754 |
$528K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
8,106 |
8,024 |
$461K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,514 |
3,385 |
$255K |
| 87070 |
|
1,421 |
1,404 |
$173K |
| 81003 |
|
3,255 |
3,111 |
$156K |
| 85018 |
|
8,311 |
8,171 |
$151K |
| 80053 |
Comprehensive metabolic panel |
5,292 |
4,962 |
$144K |
| 96127 |
|
1,395 |
1,377 |
$140K |
| 94664 |
|
1,822 |
1,744 |
$124K |
| 82247 |
|
1,211 |
772 |
$119K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
682 |
560 |
$119K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,597 |
1,530 |
$116K |
| 99174 |
|
1,020 |
1,011 |
$109K |
| 81025 |
|
949 |
916 |
$105K |
| 96161 |
|
1,045 |
1,013 |
$100K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,262 |
1,222 |
$92K |
| 87081 |
|
1,096 |
1,067 |
$92K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,293 |
3,235 |
$80K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
121 |
107 |
$79K |
| 87077 |
|
814 |
781 |
$58K |
| 90686 |
|
19,321 |
19,084 |
$38K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
491 |
474 |
$37K |
| 94010 |
|
228 |
228 |
$34K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,208 |
4,062 |
$26K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
677 |
669 |
$24K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,977 |
1,937 |
$23K |
| 94761 |
|
985 |
899 |
$21K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
156 |
153 |
$20K |
| 96160 |
|
1,468 |
1,449 |
$20K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
42,236 |
41,496 |
$17K |
| 85007 |
|
848 |
778 |
$17K |
| 85027 |
|
1,938 |
1,765 |
$15K |
| 80061 |
Lipid panel |
5,808 |
5,692 |
$14K |
| 90461 |
|
11,771 |
11,648 |
$14K |
| 81001 |
|
866 |
812 |
$13K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
245 |
203 |
$13K |
| 69210 |
|
83 |
79 |
$13K |
| 88720 |
|
73 |
64 |
$10K |
| 99177 |
|
71 |
64 |
$9K |
| 17250 |
|
14 |
13 |
$8K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,419 |
1,367 |
$7K |
| 0072A |
|
202 |
201 |
$7K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,276 |
1,234 |
$6K |
| 99173 |
|
70 |
70 |
$6K |
| 90633 |
|
8,012 |
7,821 |
$6K |
| 69209 |
|
39 |
39 |
$6K |
| 0002A |
|
141 |
141 |
$5K |
| 90670 |
|
14,574 |
14,323 |
$5K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
13 |
13 |
$4K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,550 |
2,379 |
$4K |
| 0001A |
|
183 |
180 |
$4K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,263 |
3,205 |
$4K |
| 87486 |
|
13 |
13 |
$3K |
| 0071A |
|
327 |
323 |
$3K |
| 90696 |
|
3,470 |
3,401 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
432 |
397 |
$2K |
| 90651 |
|
4,805 |
4,744 |
$2K |
| 90715 |
|
2,956 |
2,923 |
$2K |
| 0052A |
|
59 |
59 |
$1K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
25 |
25 |
$1K |
| 86140 |
|
960 |
911 |
$1K |
| 90677 |
|
1,350 |
1,303 |
$1K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
96 |
96 |
$1K |
| 99382 |
|
30 |
30 |
$1K |
| 90378 |
|
365 |
254 |
$1K |
| 90698 |
|
7,618 |
7,443 |
$983.73 |
| 94060 |
|
15 |
15 |
$970.50 |
| 90621 |
|
967 |
950 |
$787.89 |
| 0081A |
|
159 |
157 |
$787.80 |
| 90619 |
|
1,362 |
1,347 |
$663.97 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
12 |
12 |
$613.46 |
| 0082A |
|
24 |
24 |
$511.19 |
| 90656 |
|
248 |
247 |
$501.35 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
895 |
881 |
$434.51 |
| 90707 |
|
3,998 |
3,928 |
$421.90 |
| 86592 |
|
66 |
66 |
$389.00 |
| 84439 |
|
42 |
38 |
$343.29 |
| 90716 |
|
3,991 |
3,920 |
$326.43 |
| 90647 |
|
2,596 |
2,556 |
$318.34 |
| 82784 |
|
327 |
304 |
$293.77 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
599 |
510 |
$229.75 |
| 90710 |
|
3,344 |
3,282 |
$215.86 |
| 0051A |
|
52 |
52 |
$173.24 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
612 |
603 |
$170.01 |
| 90680 |
|
8,823 |
8,653 |
$156.90 |
| 86780 |
|
82 |
81 |
$150.06 |
| 87807 |
|
17 |
17 |
$142.04 |
| 82248 |
|
1,304 |
859 |
$133.69 |
| 90744 |
|
4,554 |
4,467 |
$114.97 |
| 90620 |
|
289 |
284 |
$68.91 |
| 91320 |
|
13 |
12 |
$38.24 |
| 90697 |
|
3,391 |
3,332 |
$20.17 |
| 90734 |
|
2,850 |
2,816 |
$0.02 |
| 90700 |
|
771 |
765 |
$0.02 |
| 87186 |
|
250 |
237 |
$0.00 |
| 90648 |
|
13 |
13 |
$0.00 |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
13 |
13 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
12 |
12 |
$0.00 |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
83 |
45 |
$0.00 |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
13 |
13 |
$0.00 |
| 84460 |
|
12 |
12 |
$0.00 |
| 84450 |
|
12 |
12 |
$0.00 |
| 85651 |
|
673 |
655 |
$0.00 |
| 90723 |
|
2,731 |
2,692 |
$0.00 |
| 86308 |
|
13 |
13 |
$0.00 |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
219 |
141 |
$0.00 |
| 85652 |
|
624 |
582 |
$0.00 |
| J1459 |
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg |
37 |
24 |
$0.00 |
| 96415 |
|
121 |
107 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
21 |
21 |
$0.00 |
| 90480 |
|
58 |
56 |
$0.00 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
54 |
52 |
$0.00 |
| 87581 |
|
13 |
13 |
$0.00 |